CHMP recommends Medac's generic Zometa, clears infected MabThera, seeks harmony
This article was originally published in Scrip
The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended for approval German firm Medac's generic version of Novartis' Zometa (Zoledronic acid).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.